We focused our attention to effects elicited by a sublethal dose of β3-AR antagonist SR59230A (1 μM), since its moderate toxicity at concentrations over 5 μM might be partially ascribed to its off-target effect, as we show in non-tumor cell lines such as human fibroblast and endothelial cells (Supplementary Fig. 2). The gene discussed is ADRB3; the disease is neoplasm.